AG 519

Drug Profile

AG 519

Alternative Names: AG-519

Latest Information Update: 29 Dec 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Agios Pharmaceuticals
  • Class Antianaemics
  • Mechanism of Action Pyruvate kinase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Haemolytic anaemia

Most Recent Events

  • 15 Dec 2016 Discontinued - Phase-I for Haemolytic anaemia (In volunteers) in United Kingdom (PO)
  • 15 Dec 2016 Agios withdraws an IND application in USA for Haemolytic anaemia following a verbal notification of a clinical hold from the US Food and Drug Administration
  • 04 Dec 2016 Pharmacodynamics and adverse events data from a phase I trial in Healthy volunteers presented at the 58th Annual Meeting and Exposition of the American Society of Hematology (ASH-Hem-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top